Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment

Fig. 4

Membrane integrity studies of carbosilane dendrimers and LRAs combinations. LDH assays were performed on a J89GFP lymphocyte and b THP89GFP monocyte cell lines during 24 h and 48 h. Cell lines were treated with G1-S4 (10 µM), G2-S16 (10 µM) or G3-S16 (1 µM) dendrimers. Both cell lines were treated with BRY (100 nM), PST (20 µM), PNB (40 nM) or RMD (20 nM). Non-treated (NT) cells were used as cell viability control. NT non-treated control, BRY bryostatin, PST prostratin, RMD romidepsin, PNB panobinostat. The mean values (mean ± SD) of three independent experiments are shown (*p < 0.05; **p < 0.005; ***p < 0.001)

Back to article page